Status:
COMPLETED
hsCRP in Japan Statin Treatment Against Recurrent Stroke (J-STARS hsCRP)
Lead Sponsor:
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Collaborating Sponsors:
Ministry of Health, Labour and Welfare, Japan
Hiroshima University
Conditions:
Ischemic Stroke
Eligibility:
All Genders
45-80 years
Phase:
PHASE3
Brief Summary
Inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A(HMG-CoA) reductase can play a role in preventing recurrent vascular events from ischemic heart disease patients, whose mechanism consists in not onl...
Eligibility Criteria
Inclusion
- Ischemic stroke except for cardiogenic embolism, from 1 month to 3 years after onset
- Hyperlipidemia and total cholesterol level of 180-240mg/dl without the prescription of statin within previous 30 days
- Able to visit outpatient department
- Informed consent on the form filled in by the patient.
Exclusion
- Ischemic stroke of other determined cause according to the TOAST classification
- Ischemic heart disease and necessary to use statin
- Hemorrhagic disorders
- Platelet count \<=100,000/ul within 3 months prior to study start
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST)\>= 100IU/L within 3 months prior to study start
- Serum creatinine \>=2.0mg/dl within 3 months prior to study start
- A scheduled operation
- The presence of malignant disorder
Key Trial Info
Start Date :
March 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
1095 Patients enrolled
Trial Details
Trial ID
NCT00361699
Start Date
March 1 2004
Last Update
April 25 2016
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Hiroshima University Hospital
Hiroashima, Hiroshima, Japan, 734-8551
2
Osaka University
Suita-shi, Osaka, Japan, 565-0871